SEC Contract Filing

Filing Date: 2015-11-05

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
 <TITLE>Arbutus Biopharma Corp.: Exhibit 10.2 - Filed by newsfilecorp.com</TITLE>
 <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=right><B>CONFIDENTIAL <BR>Execution Version </B></P>
<P align=justify>Confidential treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the
confidentiality request. Omissions are designated as [***]. A complete version
of this exhibit has been filed separately with the Securities and Exchange
Commission. </P>
<P align=center><B>LICENSE AGREEMENT </B></P>
<P align=center>Dated December 30, 2014 </P>
<P align=center>By and Between </P>
<P align=center>Cytos Biotechnology Ltd </P>
<P align=center>and </P>
<P align=center>OnCore Biopharma, Inc. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center><B>LICENSE AGREEMENT </B></P>
<P align=justify style="text-indent:5%">THIS LICENSE AGREEMENT (the &#147;<B>Agreement</B>&#148;) is dated as of
December 30, 2014 (the &#147;<B>Execution Date</B>&#148;) by and between Cytos
Biotechnology Ltd, a Swiss company having a place of business at Wagistrasse 25,
8952 Schlieren, Switzerland (&#147;<B>Licensor</B>&#148;), and OnCore Biopharma, Inc., a
Delaware corporation having a place of business at 3805 Old Easton Road,
Doylestown, PA 18902, USA (&#147;<B>OnCore</B>&#148;). Licensor and OnCore may be referred
to herein as a &#147;<B>Party</B>&#148; or, collectively, as &#147;<B>Parties</B>&#148;. </P>
<P align=center><B>RECITALS: </B></P>
<P align=justify style="text-indent:5%">WHEREAS, Licensor is engaged in the development of products
based on its Qb VLP platform technology and owns certain intellectual property
covering Licensed Compounds and Licensed Products; </P>
<P align=justify style="text-indent:5%">WHEREAS, OnCore is engaged in the research, development, and
manufacturing of pharmaceutical products for the treatment of hepatitis and is
interested in developing, manufacturing and commercializing Licensed Products
for the treatment of hepatitis and potentially other viral infections; and </P>
<P align=justify style="text-indent:5%">WHEREAS, OnCore desires to license from Licensor and Licensor
wishes to license to OnCore, on an exclusive basis, the right to develop,
manufacture and commercialize Licensed Compounds and Licensed Products in the
Field. </P>
<P align=justify style="text-indent:5%">Now, THEREFORE, in consideration of the various promises and
undertakings set forth herein, the Parties agree as follows: </P>
<P align=center><B>ARTICLE 1 <BR>DEFINITIONS </B></P>
<P align=justify style="text-indent:5%">Unless otherwise specifically provided herein, the following
terms shall have the following meanings: </P>
<P align=justify style="text-indent:5%"><b>1.1</b>&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Additional Fields</B>&#148;
mean the diagnosis, prevention and/or treatment of any viral infections other
than influenza virus infections and hepatitis virus infections, with each viral
infection representing a single &#147;Additional Field.&#148; </P>
<P align=justify style="text-indent:5%"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Adverse Event</B>&#148; means
any serious untoward medical occurrence in a patient or subject who is
administered Licensed Product, but only if and to the extent that such serious
untoward medical occurrence is required under Laws to be reported to applicable
Regulatory Authorities. </P>
<P align=justify style="text-indent:5%"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Affiliate</B>&#148; means a
Person that controls, is controlled by or is under common control with a Party,
but only for so long as such control exists. For the purposes of this Section
1.3, the word &#147;control&#148; (including, with correlative meaning, the terms
&#147;controlled by&#148; or &#147;under the common control with&#148;) means the actual power,
either directly or indirectly through one or more intermediaries, to direct the
management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting
stock of such entity, or by contract or otherwise. </P>
<P align=center>1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=justify style="text-indent:5%"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Baseline Data</B>&#148; means
any and all <I>in vitro</I> or <I>in vivo</I> efficacy, safety or toxicology
data, whether preclinical or clinical, relating in any way to the use of a
product comprising a Qb VLP for the diagnosis, prevention and/or treatment of
any and all viral infections for which an Offer Notice was provided, which is in
the possession of Licensor and which Licensor may rightfully provide to OnCore.
Licensor shall use its best efforts to obtain any and all data that would
otherwise be Baseline Data but for Licensor&#146;s inability to rightfully provide it
to OnCore. </P>
<P align=justify style="text-indent:5%"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Business Day</B>&#148; means
a day other than Saturday or Sunday on which banking institutions in New York,
New York are open for business. </P>
<P align=justify style="text-indent:5%"><B>1.6&nbsp;&nbsp;&nbsp;&nbsp; </B>&#147;<B>Calendar Quarter</B>&#148;
means each three (3) month period commencing January 1, April 1, July 1 or
October 1 of any year; provided, however, that (a) the first Calendar Quarter of
the Term shall extend from the Closing Date to the end of the first full
Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall
end upon the expiration or termination of this Agreement. </P>
<